OR WAIT 15 SECS
Lubrizol’s purchase intravascular and nonvascular devices developer Bavaria Medizin Technologie, extends its scope of services.
The Lubrizol Corporation has announced the acquisition of Bavaria Medizin Technologie (BMT) GmbH, a designer and manufacturer of intravascular and nonvascular devices, including drug-coated balloons. The acquisition expands Lubrizol’s footprint in contact development and manufacturing of medical devices and pharmaceuticals.
According to a July 15, 2019 press statement, the acquisition will build upon the company’s product development and design, manufacturing expertise, and provide access to proprietary catheter and balloon technologies. BMT, which has locations in Munich, Germany and Sibiu, Romania, will be a wholly owned subsidiary of The Lubrizol Corporation, in the Health business of Lubrizol Life Science.
BMT developedbthe first commercial drug-coated balloon catheter, holds more than 50 patents, and offers private label manufacturing of proprietary catheters and balloons along with original equipment manufacturing services.
“Lubrizol continues to invest in opportunities that position us as a full-service development partner for innovative OEMs in the interventional space,” said Uwe Winzen, general manager of the health business of Lubrizol Life Science in the press statement. “Our customers will benefit from additional design capabilities, an increased global footprint, and synergies with our existing formulation and manufacturing services.”